This pattern was slightly inconsistent with the current guidelines for clinical use of blood by the National Blood Centre Ministry of Health Malaysia, as the Hb level around 7- 8 g/dl is appropriate to control symptomatic anaemia during the marrow-suppressive treatment of cancer (12). Here, GSTM1 is linked to cancer.